ir.immudyne.com ir.immudyne.com

ir.immudyne.com

ImmuDyne, Inc. (IMMD)

ImmuDyne, Inc. (OTCQB: IMMD) is a biotech Company focused on R&D and commercialization of a proprietary yeast-derived beta-glucan, Beta-1/3,1/6-glucan, for serious unmet needs including epidermal, anti-infective, anti-cancer, and anti-inflammatory markets. Beta-glucan has been published in over 6000 scientific papers and is an immune-modulator that binds to and activates Natural Killer (NK), dendritic (DC), and other immune cells, as shown in Figure 1 (below). Figure 1. Beta-Glucan Mechanism of Action.

http://ir.immudyne.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR IR.IMMUDYNE.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

March

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 3.8 out of 5 with 11 reviews
5 star
4
4 star
3
3 star
3
2 star
0
1 star
1

Hey there! Start your review of ir.immudyne.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

0.6 seconds

FAVICON PREVIEW

  • ir.immudyne.com

    16x16

  • ir.immudyne.com

    32x32

CONTACTS AT IR.IMMUDYNE.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
ImmuDyne, Inc. (IMMD) | ir.immudyne.com Reviews
<META>
DESCRIPTION
ImmuDyne, Inc. (OTCQB: IMMD) is a biotech Company focused on R&D and commercialization of a proprietary yeast-derived beta-glucan, Beta-1/3,1/6-glucan, for serious unmet needs including epidermal, anti-infective, anti-cancer, and anti-inflammatory markets. Beta-glucan has been published in over 6000 scientific papers and is an immune-modulator that binds to and activates Natural Killer (NK), dendritic (DC), and other immune cells, as shown in Figure 1 (below). Figure 1. Beta-Glucan Mechanism of Action.
<META>
KEYWORDS
1 about immudyne
2 overview
3 management
4 partners
5 corporate presentation
6 careers
7 our science
8 puracere
9 immune health
10 doctor recommendations
CONTENT
Page content here
KEYWORDS ON
PAGE
about immudyne,overview,management,partners,corporate presentation,careers,our science,puracere,immune health,doctor recommendations,scientific studies,areas of focus,strategic additives,direct to consumer,licensing and jv,investors,news / events,news
SERVER
Apache
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

ImmuDyne, Inc. (IMMD) | ir.immudyne.com Reviews

https://ir.immudyne.com

ImmuDyne, Inc. (OTCQB: IMMD) is a biotech Company focused on R&D and commercialization of a proprietary yeast-derived beta-glucan, Beta-1/3,1/6-glucan, for serious unmet needs including epidermal, anti-infective, anti-cancer, and anti-inflammatory markets. Beta-glucan has been published in over 6000 scientific papers and is an immune-modulator that binds to and activates Natural Killer (NK), dendritic (DC), and other immune cells, as shown in Figure 1 (below). Figure 1. Beta-Glucan Mechanism of Action.

INTERNAL PAGES

ir.immudyne.com ir.immudyne.com
1

All SEC Filings :: ImmuDyne, Inc. (IMMD)

http://ir.immudyne.com/all-sec-filings

Quarterly report pursuant to Section 13 or 15(d). Quarterly report pursuant to Section 13 or 15(d). Quarterly report pursuant to Section 13 or 15(d). 7453 Empire Dr. Suite #300, Florence KY, 41042.

2

Board of Directors :: ImmuDyne, Inc. (IMMD)

http://ir.immudyne.com/board-of-directors

Anthony G. Bruzzese, M.D. Chairman of the Board. President, Chief Executive Officer, and Director. Mark McLaughlin has an extensive business background and financial expertise. With 10 years as an investment advisor at Lehman Brothers and 3 years at Oppenheimer and Company, Mr. McLaughlin gained experience across raising capital and business development. Sven Rohmann, MD, PhD, MBA. Global Chief Medical Office, Director. In addition to his clinical expertise, he has worked across product development and m...

3

Email Alerts :: ImmuDyne, Inc. (IMMD)

http://ir.immudyne.com/email-alerts

Please fill out the form below to receive company press releases via email when they occur. Annual & Quarterly Reports. We respect your privacy. We do not sell, rent, or loan any information to any third party. Any information you give us is held with the utmost care and security, and will be used only in ways to which you have consented. 7453 Empire Dr. Suite #300, Florence KY, 41042.

4

Financials :: ImmuDyne, Inc. (IMMD)

http://ir.immudyne.com/financials

Consolidated Balance Sheets - USD ($). Sep 30, 2016. Dec 31, 2015. Trade accounts receivable, net. Accounts payable and accrued expenses. Notes payable, net of discount. Immudyne, Inc. Stockholders' equity. Common stock, $0.01 par value; 50,000,000 shares authorized, 34,697,875 and 32,010,375 shares issued, 34,678,512 and 32,010,375 outstanding as of September 30, 2016 and December 31, 2015, respectively. Treasury stock,19,363 shares, at cost. Total Immudyne, Inc. Stockholders' Equity. Amount due from cu...

5

Press Releases :: ImmuDyne, Inc. (IMMD)

http://ir.immudyne.com/press-releases

ImmuDyne Provides 2017 Business Outlook. Mar 6, 2017. ImmuDyne Appoints Chief Operating Officer/Chief Technology Officer. Feb 23, 2017. ImmuDyne: Second Patent Issued for Topical Treatment of Hair Loss/Alopecia; Q1 Launch Scheduled. Jan 24, 2017. Immudyne Announces Definitive Endorsement Agreement with Leading Dermatologist. Dec 7, 2016. ImmuDyne Announces Q3 2016 Net Sales Up 395%, Adjusted Non-GAAP Net Income. Nov 15, 2016. ImmuDyne Announces Preliminary Q3 Revenues. Oct 11, 2016. Sep 9, 2016.

UPGRADE TO PREMIUM TO VIEW 4 MORE

TOTAL PAGES IN THIS WEBSITE

9

LINKS TO THIS WEBSITE

immudyne.com immudyne.com

Cart | Immudyne, Inc

https://immudyne.com/checkout

Your cart is currently empty. 7453 Empire Connector Dr. #300, Florence KY, 41032.

immudyne.com immudyne.com

Home | Immudyne, Inc

http://immudyne.com/home

Immudyne’s proprietary and innovative Yeast Beta Glucan ingredient and delivery technology have attracted the attention of leading cosmetic companies, healthcare distributors, physician groups and marketing organizations. (Learn more). 7453 Empire Connector Dr. #300, Florence KY, 41032.

UPGRADE TO PREMIUM TO VIEW 7 MORE

TOTAL LINKS TO THIS WEBSITE

9

SOCIAL ENGAGEMENT



OTHER SITES

ir.imagesystems.tv ir.imagesystems.tv

Investor Relations - Image Systems

Tillbaka till imagesystems.se. Externa kontakter med marknaden hanteras av bolagets VD. Image Systems is a public company on the Swedish stock exchange (Nasdaq OMX) listed on the Small Cap-list, under the ticker IS. The IR section of this web site is only available in Swedish. It contains general financial information about the company and its shares. The section also contains all the latest published financial information and press releases from Image Systems. Jag har glömt mitt lösenord.

ir.imation.com ir.imation.com

Imation - Investor Relations - Investor Relations Home

Q2 2015 Imation Corp Earnings Conference Call. 160;at 9:00 am CT. Imation is a global scalable storage and data security company. The Company's portfolio includes tiered storage and security offerings for business and products designed to manage audio and video information in the home. Imation reaches customers in more than 100 countries through a powerful global distribution network and well recognized brands. Additional information about Imation is available at www.imation.com. 160;- 0.09.

ir.imde.ac.cn ir.imde.ac.cn

中国科学院水利部成都山地灾害与环境研究所机构知识库(IMHE OpenIR): Home

Have you forgotten your password? Journal . [694]. Journal . [753]. 20世纪80年代末以来中国土地利用变化的基本. [期刊论文, 2015-08]. 龙门山地区的动物资源 [期刊论文, 2015-08]. 高分辨率地震勘探 [期刊论文, 2015-08]. 四川棉花生产布局问题 [期刊论文, 2015-08]. 卧龙自然保护区日臻完善 [期刊论文, 2015-08]. 对美国环境保护的几点考察 [期刊论文, 2015-08]. 四川贡嘎山地区的泥石流及其防治 [期刊论文, 2015-08]. 四川乐山五通石麟镇原始桫椤林科学考察报告 [期刊论文, 2015-08]. 计算机处理摄谱法光谱分析数据 [期刊论文, 2015-08]. 对川西九龙地区农、林、牧生产布局的初步探. [期刊论文, 2015-08]. Choose a community to browse its collections. Journal of Mountain Science. 2 Ecological and E. 5 Effects of human.

ir.immersion.com ir.immersion.com

Investor | Immersion Corporation

Skip to main navigation. Where can I experience haptics? San Jose, California, 95134, USA. T: 1 408.467.1900. F: 1 408.467.1901. Invest in the Future. IR News and Events. Mar 08, 2018. Immersion Files Additional Lawsuits Against Samsung in U.S. and China. Mar 07, 2018. Feb 22, 2018 at 5:00 PM EST. Q4 2017 Immersion Corporation Earnings Conference Call. Nov 2, 2017 at 5:00 PM EDT. Q3 2017 Immersion Corporation Earnings Conference Call. View all Stock Information. San Jose, California, 95134.

ir.immomo.com ir.immomo.com

Momo - Investors - Investor Home

Stock Quote and Chart. Momo Second Quarter 2015 Earnings Conference Call. 160;at 9:00 pm ET. Momo Second Quarter 2015 Earnings Conference Call. Wednesday, August 19, 2015 . 9:00 pm ET  . Click here for webcast. Click here to add this event to your calendar. Momo connects people in a personal and lively way. Momo has become an integral part of the daily lives of many people in China, where the increasing proliferation of smartphones and netw. Momo First Quarter 2015 Earnings Conference Call. 160; 0.41.

ir.immudyne.com ir.immudyne.com

ImmuDyne, Inc. (IMMD)

ImmuDyne, Inc. (OTCQB: IMMD) is a biotech Company focused on R&D and commercialization of a proprietary yeast-derived beta-glucan, Beta-1/3,1/6-glucan, for serious unmet needs including epidermal, anti-infective, anti-cancer, and anti-inflammatory markets. Beta-glucan has been published in over 6000 scientific papers and is an immune-modulator that binds to and activates Natural Killer (NK), dendritic (DC), and other immune cells, as shown in Figure 1 (below). Figure 1. Beta-Glucan Mechanism of Action.

ir.immunedesign.com ir.immunedesign.com

Investor Relations | Immune Design

Harnessing the Immune System to Fight Disease. Infectious Diseases & Allergy. Annual Reports and Proxies. Immune Design is a clinical stage immunotherapy company employing next-generation. Aug 12, 2015. Immune Design Reports Second Quarter 2015 Financial Results. Aug 12, 2015. Immune Design Announces Phase 2 Cancer Immunotherapy Trial Collaboration. View all news releases ». Aug 12, 2015 at 1:30 PM PT. Immune Design Second Quarter 2015 Financial Results. Jun 3, 2015 at 2:00 PM ET. Day High: 17.39.

ir.immunicum.com ir.immunicum.com

Immunicum AB - Investerare

Företrädesemission - läs mer. Ladda ner prospekt. Klinisk Fas I/II-studie (RCC). Välkommen till Immunicums investerarsidor! Här presenteras information som kan vara av intresse för Bolagets aktieägare, analytiker och andra intressenter. För ytterligare information eller frågor kontakta VD Jamal El-Mosleh. Jamal El-Mosleh, VD. Tel: 031- 41 50 53. E-post: jamal.el-mosleh@immunicum.com. Visa alla meddelanden ». 13 augusti, 2015. Magnus Persson föreslås till ny styrelseledamot i Immunicum. 5 augusti, 2015.

ir.impaccompanies.com ir.impaccompanies.com

Investor Relations

Join our email list Sign Up. Follow us on LinkedIn. Your browser does not support iframes. Stay Connected with Impac Companies. Contact Impac Mortgage Corp. (NMLS #128231), for purchase and refi, including Jumbo, Conventional, FHA/VA/USDA, 203k Home Renovation and Reverse Mortgage programs. An agency-direct lender, Impac Mortgage Corp. Wholesale offers a full range of conventional, jumbo, and AltQM loan programs. Innovative thinking, strength of service, personal commitment. As of August 7, 2015 -. Impac...

ir.imperial.com ir.imperial.com

Investor Relations - Imperial Holdings, Inc.

Imperial Finance and Trading. Call Toll Free: 1-888-364-6775. Our Team of Leaders. Annual Reports and Proxies. We are a specialty finance company providing customized liquidity solutions to owners of illiquid financial assets. Imperial purchases and sells life insurance policies issued by insurance companies generally rated "A " or better by Standard and Poor's or "A" or better by am Best Company. As part of its core philosophy Imperial is focused on:. Annual Shareholders Meeting Presentation.

ir.imperialindustries.com ir.imperialindustries.com

imperialindustries.com